Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Pathophysiology of AKI from Sepsis to SARS-COV-2 Infection: Molecular Basis,...
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Pathophysiology of AKI from Sepsis to SARS-COV-2 Infection: Molecular Basis, Diagnosis and Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 9404

Special Issue Editors

Prof. Dr. Giuseppe Castellano

E-Mail Website
Guest Editor
Nephrology, Dialysis and Transplantation Unit, Università degli Studi di Foggia, Foggia, Italy
Interests: acute kidney injury; sepsis, renal transplantation; complement system; fibrosis and aging; dendritic cells
Special Issues, Collections and Topics in MDPI journals
Dr. Rossana Franzin

E-Mail Website
Guest Editor
Department of Emergency and Organ Transplantation, University of Bari, 70121 Bari, Italy
Interests: acute kidney injury; renal aging; complement system; renal transplantation; endothelial-to-mesenchymal transition
Special Issues, Collections and Topics in MDPI journals
Dr. Alessandra Stasi

E-Mail Website
Guest Editor
Nephrology Unit, Department of Emergency and Organ Transplantation, University of Bari "Aldo Moro", Bari, Italy
Interests: sepsis; acute kidney injury; infection; molecular biology; animal studies; endothelial dysfunction; inflammation; complement system; fibrosis; aging

Special Issue Information

Dear Colleagues,

Sepsis remains a major cause of morbidity and mortality worldwide, with more than 11 million deaths annually. The syndrome represents a life-threatening systemic disease associated with an overwhelmed host response due to invasion of the bloodstream by bacteria, viruses, fungi, or parasites. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19), shares common features with sepsis as multiorgan dysfunction and is currently defined as “viral sepsis”. In recent years, these systemic inflammatory disorders have attracted the interest of several researchers because of their involvement in human health.

In critically ill patients, renal dysfunction is associated with an unacceptably high morbidity/mortality risk, progression toward chronic kidney disease, and increased health resource utilization. Patients with acute kidney injury (AKI) are twice as likely to require invasive mechanical ventilation and renal replacement therapies. Given the paucity of knowledge about optimal prevention and treatment strategies for sepsis and COVID-19-related AKI, specific biological markers for an early and reliable diagnosis of AKI and response to therapies should be defined. This last point is crucial in the management of severe forms of sepsis and COVID-19 and may have an immediate application in our daily approach to these patients. In addition, pre-clinical studies with animal models and in vitro experiments should provide additional insights into the physiopathological aspects of these systemic inflammatory disorders. Exploring new pathogenetic mechanisms, with special regard to the role of soluble and cellular components of innate immunity, would identify novel targets and innovative therapeutic approaches.

In this Special Issue, we will gather original research papers and reviews from different experts in the field that bring to the forefront new advances in pathophysiology and treatment of sepsis and COVID-19-associated AKI.

Prof. Dr. Giuseppe Castellano
Dr. Rossana Franzin
Dr. Alessandra Stasi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sepsis
  • SARS-CoV-2
  • Acute Kidney Injury (AKI)
  • experimental and clinical studies
  • molecular mechanisms
  • therapeutic targets
  • emerging biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1426 KiB  
Article
Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study
by Oliver Gross, Onnen Moerer, Thomas Rauen, Jan Böckhaus, Elion Hoxha, Achim Jörres, Matthias Kamm, Amin Elfanish, Wolfram Windisch, Michael Dreher, Juergen Floege, Stefan Kluge, Christian Schmidt-Lauber, Jan-Eric Turner, Samuel Huber, Marylyn M. Addo, Simone Scheithauer, Tim Friede, Gerald S. Braun, Tobias B. Huber and Sabine Blaschkeadd Show full author list remove Hide full author list
J. Clin. Med. 2021, 10(14), 3049; https://doi.org/10.3390/jcm10143049 - 9 Jul 2021
Cited by 12 | Viewed by 6262
Abstract
In COVID-19, guidelines recommend a urinalysis on hospital admission as SARS-CoV-2 renal tropism, post-mortem, was associated with disease severity and mortality. Following the hypothesis from our pilot study, we now validate an algorithm harnessing urinalysis to predict the outcome and the need for [...] Read more.
In COVID-19, guidelines recommend a urinalysis on hospital admission as SARS-CoV-2 renal tropism, post-mortem, was associated with disease severity and mortality. Following the hypothesis from our pilot study, we now validate an algorithm harnessing urinalysis to predict the outcome and the need for ICU resources on admission to hospital. Patients were screened for urinalysis, serum albumin (SA) and antithrombin III activity (AT-III) obtained prospectively on admission. The risk for an unfavorable course was categorized as (1) “low”, (2) “intermediate” or (3) “high”, depending on (1) normal urinalysis, (2) abnormal urinalysis with SA ≥ 2 g/dL and AT-III ≥ 70%, or (3) abnormal urinalysis with SA or AT-III abnormality. Time to ICU admission or death served as the primary endpoint. Among 223 screened patients, 145 were eligible for enrollment, 43 falling into the low, 84 intermediate, and 18 into high-risk categories. An abnormal urinalysis significantly elevated the risk for ICU admission or death (63.7% vs. 27.9%; HR 2.6; 95%-CI 1.4 to 4.9; p = 0.0020) and was 100% in the high-risk group. Having an abnormal urinalysis was associated with mortality, a need for mechanical ventilation, extra-corporeal membrane oxygenation or renal replacement therapy. In conclusion, our data confirm that COVID-19-associated urine abnormalities on admission predict disease aggravation and the need for ICU (ClinicalTrials.gov number NCT04347824). Full article
(This article belongs to the Special Issue Pathophysiology of AKI from Sepsis to SARS-COV-2 Infection: Molecular Basis, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 396 KiB  
Review
Acute Kidney Injury and Blood Purification Techniques in Severe COVID-19 Patients
by Marianna Napoli, Michele Provenzano, Lilio Hu, Claudia Bini, Chiara Abenavoli, Gaetano La Manna and Giorgia Comai
J. Clin. Med. 2022, 11(21), 6286; https://doi.org/10.3390/jcm11216286 - 25 Oct 2022
Cited by 1 | Viewed by 2435
Abstract
Although most patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) experience respiratory manifestations, multi-organ dysfunction is frequent. Almost 20% of hospitalized patients with SARS-CoV-2 infection develop acute kidney injury (AKI). The pathophysiology of AKI is a result of both the direct and indirect [...] Read more.
Although most patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) experience respiratory manifestations, multi-organ dysfunction is frequent. Almost 20% of hospitalized patients with SARS-CoV-2 infection develop acute kidney injury (AKI). The pathophysiology of AKI is a result of both the direct and indirect effects of SARS-CoV-2 infection, including systemic inflammatory responses, the activation of the renin-angiotensin-aldosterone system (RAAS), and endothelial and coagulative dysfunction. Underlying SARS-CoV-2 infection-associated AKI, an immunological hyper-response with an unbalanced innate and adaptative response defined as a “cytokine storm” has emerged. Numerous agents have been tested in an effort to mitigate the cytokine storm, and a range of extracorporeal cytokine removal techniques have been proposed as potential therapeutic options. In the present review, we summarize the main pathogenetic mechanisms underlying COVID-19-related AKI in order to provide an appropriate individual therapeutic strategy to improve clinical outcomes and limit the progression of early disease. Full article
(This article belongs to the Special Issue Pathophysiology of AKI from Sepsis to SARS-COV-2 Infection: Molecular Basis, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop